Welcome!

News Feed Item

Metachromatic Leukodystrophy (MLD) Global Clinical Trials Review, H2, 2014

NEW YORK, Aug. 5, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Metachromatic Leukodystrophy (MLD) Global Clinical Trials Review, H2, 2014

http://www.reportlinker.com/p02256137/Metachromatic-Leukodystrophy-MLD-Global-Clinical-Trials-Review-H2-2014.html

Metachromatic Leukodystrophy (MLD) Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Metachromatic Leukodystrophy (MLD) Global Clinical Trials Review, H2, 2014" provides data on the Metachromatic Leukodystrophy (MLD) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metachromatic Leukodystrophy (MLD). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metachromatic Leukodystrophy (MLD). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Metachromatic Leukodystrophy (MLD) 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Metachromatic Leukodystrophy (MLD) to Central Nervous System Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16

Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Metachromatic Leukodystrophy (MLD) to Central Nervous System Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Unaccomplished Trials of Metachromatic Leukodystrophy (MLD) 24
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27

Prominent Sponsors 28
Top Companies Participating in Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials 29
Prominent Drugs 30
Clinical Trial Profiles 31
Clinical Trial Overview of Top Companies 31
Shire Plc 31
Clinical Trial Overview of Shire Plc 31
The Cooper Companies, Inc. 32
Clinical Trial Overview of The Cooper Companies, Inc. 32
GlaxoSmithKline plc 33
Clinical Trial Overview of GlaxoSmithKline plc 33
Cytomedix, Inc. 34
Clinical Trial Overview of Cytomedix, Inc. 34
Clinical Trial Overview of Top Institutes / Government 35
University of Louisville 35
Clinical Trial Overview of University of Louisville 35
IRCCS San Raffaele Milano 36
Clinical Trial Overview of IRCCS San Raffaele Milano 36

Fondazione San Raffaele del Monte Tabor 37
Clinical Trial Overview of Fondazione San Raffaele del Monte Tabor 37
University of Rostock 38
Clinical Trial Overview of University of Rostock 38
Fairview University Medical Center 39
Clinical Trial Overview of Fairview University Medical Center 39
New York Medical College 40
Clinical Trial Overview of New York Medical College 40
Masonic Cancer Center 41
Clinical Trial Overview of Masonic Cancer Center 41
Institut National de la Sante et de la Recherche Medicale 42
Clinical Trial Overview of Institut National de la Sante et de la Recherche Medicale 42
National Center for Research Resources 43
Clinical Trial Overview of National Center for Research Resources 43
Assistance Publique - Hopitaux de Paris 44
Clinical Trial Overview of Assistance Publique - Hopitaux de Paris 44
Five Key Clinical Profiles 45
Appendix 68
Abbreviations 68
Definitions 68
Research Methodology 69
Secondary Research 69
About GlobalData 70
Contact Us 70
Disclaimer 70
Source 70

List of Tables

Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials by Region, 2014* 7
Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 10
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 14
Proportion of Metachromatic Leukodystrophy (MLD) to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 15
Metachromatic Leukodystrophy (MLD) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16

Metachromatic Leukodystrophy (MLD) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Metachromatic Leukodystrophy (MLD) to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 18
Metachromatic Leukodystrophy (MLD) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials by Phase, 2014* 20
Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 21
Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 22
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 23

Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Suspended Clinical Trials, 2014* 24
Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Terminated Clinical Trials, 2014* 25
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Metachromatic Leukodystrophy (MLD) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 27
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 29
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 30
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by Shire Plc, 2014* 31
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by The Cooper Companies, Inc., 2014* 32
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014* 33
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by Cytomedix, Inc., 2014* 34
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Louisville, 2014* 35
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by IRCCS San Raffaele Milano, 2014* 36

Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by Fondazione San Raffaele del Monte Tabor, 2014* 37
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Rostock, 2014* 38
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by Fairview University Medical Center, 2014* 39
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by New York Medical College, 2014* 40
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by Masonic Cancer Center, 2014* 41
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by Institut National de la Sante et de la Recherche Medicale, 2014* 42
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by National Center for Research Resources, 2014* 43
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by Assistance Publique - Hopitaux de Paris, 2014* 44

List of Figures

Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2014* 10
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2014* 14
Proportion of Metachromatic Leukodystrophy (MLD) to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 15

Metachromatic Leukodystrophy (MLD) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Metachromatic Leukodystrophy (MLD) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Metachromatic Leukodystrophy (MLD) to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 18
Metachromatic Leukodystrophy (MLD) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials by Phase (%), 2014* 20
Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 21
Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 22
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 23
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Metachromatic Leukodystrophy (MLD) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 27
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 29
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 30
GlobalData Methodology 69

To order this report: Metachromatic Leukodystrophy (MLD) Global Clinical Trials Review, H2, 2014
http://www.reportlinker.com/p02256137/Metachromatic-Leukodystrophy-MLD-Global-Clinical-Trials-Review-H2-2014.html

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
WebRTC is bringing significant change to the communications landscape that will bridge the worlds of web and telephony, making the Internet the new standard for communications. Cloud9 took the road less traveled and used WebRTC to create a downloadable enterprise-grade communications platform that is changing the communication dynamic in the financial sector. In his session at @ThingsExpo, Leo Papadopoulos, CTO of Cloud9, discussed the importance of WebRTC and how it enables companies to focus...
Qosmos has announced new milestones in the detection of encrypted traffic and in protocol signature coverage. Qosmos latest software can accurately classify traffic encrypted with SSL/TLS (e.g., Google, Facebook, WhatsApp), P2P traffic (e.g., BitTorrent, MuTorrent, Vuze), and Skype, while preserving the privacy of communication content. These new classification techniques mean that traffic optimization, policy enforcement, and user experience are largely unaffected by encryption. In respect wit...
ReadyTalk has expanded the capabilities of the FoxDen collaboration platform announced late last year to include FoxDen Connect, an in-room video collaboration experience that launches with a single touch. With FoxDen Connect, users can now not only engage in HD video conferencing between iOS and Android mobile devices or Chrome browsers, but also set up in-person meeting rooms for video interactions. A host’s mobile device automatically recognizes the presence of a meeting room via beacon tech...
Manufacturers are embracing the Industrial Internet the same way consumers are leveraging Fitbits – to improve overall health and wellness. Both can provide consistent measurement, visibility, and suggest performance improvements customized to help reach goals. Fitbit users can view real-time data and make adjustments to increase their activity. In his session at @ThingsExpo, Mark Bernardo Professional Services Leader, Americas, at GE Digital, discussed how leveraging the Industrial Internet a...
On Dice.com, the number of job postings asking for skill in Amazon Web Services increased 76 percent between June 2015 and June 2016. Salesforce.com saw its own skill mentions increase 37 percent, while DevOps and Cloud rose 35 percent and 28 percent, respectively. Even as they expand their presence in the cloud, companies are also looking for tech professionals who can manage projects, crunch data, and figure out how to make systems run more autonomously. Mentions of ‘data science’ as a skill ...
In his session at Cloud Expo, Robert Cohen, an economist and senior fellow at the Economic Strategy Institute, will provide economic scenarios that describe how the rapid adoption of software-defined everything including cloud services, SDDC and open networking will change GDP, industry growth, productivity and jobs. This session will also include a drill down for several industries such as finance, social media, cloud service providers and pharmaceuticals.
IoT generates lots of temporal data. But how do you unlock its value? You need to discover patterns that are repeatable in vast quantities of data, understand their meaning, and implement scalable monitoring across multiple data streams in order to monetize the discoveries and insights. Motif discovery and deep learning platforms are emerging to visualize sensor data, to search for patterns and to build application that can monitor real time streams efficiently. In his session at @ThingsExpo, ...
Ixia (Nasdaq: XXIA) has announced that NoviFlow Inc.has deployed IxNetwork® to validate the company’s designs and accelerate the delivery of its proven, reliable products. Based in Montréal, NoviFlow Inc. supports network carriers, hyperscale data center operators, and enterprises seeking greater network control and flexibility, network scalability, and the capacity to handle extremely large numbers of flows, while maintaining maximum network performance. To meet these requirements, NoviFlow in...
Choosing the right cloud for your workloads is a balancing act that can cost your organization time, money and aggravation - unless you get it right the first time. Economics, speed, performance, accessibility, administrative needs and security all play a vital role in dictating your approach to the cloud. Without knowing the right questions to ask, you could wind up paying for capacity you'll never need or underestimating the resources required to run your applications.
Security, data privacy, reliability and regulatory compliance are critical factors when evaluating whether to move business applications from in-house client hosted environments to a cloud platform. In her session at 18th Cloud Expo, Vandana Viswanathan, Associate Director at Cognizant, In this session, will provide an orientation to the five stages required to implement a cloud hosted solution validation strategy.
"delaPlex is a software development company. We do team-based outsourcing development," explained Mark Rivers, COO and Co-founder of delaPlex Software, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Ovum, a leading technology analyst firm, has published an in-depth report, Ovum Decision Matrix: Selecting a DevOps Release Management Solution, 2016–17. The report focuses on the automation aspects of DevOps, Release Management and compares solutions from the leading vendors.
Continuous testing helps bridge the gap between developing quickly and maintaining high quality products. But to implement continuous testing, CTOs must take a strategic approach to building a testing infrastructure and toolset that empowers their team to move fast. Download our guide to laying the groundwork for a scalable continuous testing strategy.
Adding public cloud resources to an existing application can be a daunting process. The tools that you currently use to manage the software and hardware outside the cloud aren’t always the best tools to efficiently grow into the cloud. All of the major configuration management tools have cloud orchestration plugins that can be leveraged, but there are also cloud-native tools that can dramatically improve the efficiency of managing your application lifecycle. In his session at 18th Cloud Expo, ...
SYS-CON Events announced today that LeaseWeb USA, a cloud Infrastructure-as-a-Service (IaaS) provider, will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. LeaseWeb is one of the world's largest hosting brands. The company helps customers define, develop and deploy IT infrastructure tailored to their exact business needs, by combining various kinds cloud solutions.